Sorrento Therapeutics (NASDAQ:SRNE) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Sorrento Therapeutics (NASDAQ:SRNEGet Free Report) in a research note issued to investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Performance

Shares of SRNE stock opened at $0.01 on Monday. Sorrento Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.42. The firm has a fifty day moving average of $0.02 and a 200-day moving average of $0.05.

About Sorrento Therapeutics

(Get Free Report)

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.

Featured Articles

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.